All In Biotech

NDA 212905 · Verrica Pharms

Ycanth

Cantharidin · Topical

Last checked: Nov 19, 2026Latest source record: Jul 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Jul 21, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

16

0 Phase 3, 0 recruiting

FAERS reports

183

33 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 13, 2024.

YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. ( 1 )

Mechanism: The mechanism of action of cantharidin in the treatment of molluscum contagiosum is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 21, 2023 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • YCANTH · CANTHARIDIN 0.7% · SOLUTION, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cantharidin" as an intervention, any sponsor and status, largest first.

All 16 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • application site vesicles78
  • application site pain53
  • blister30
  • pain16
  • application site burn12
  • blister rupture8
  • hypersensitivity8
  • application site erythema7
  • drug ineffective7
  • accidental exposure to product6
  • chemical burn6
  • wrong technique in product usage process6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20121
20151
20161
20195
20211
20221
20239
202458
202559
202646

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ycanth (Cantharidin)

2024 spending

$15K

Beneficiaries

n/a

16 claims

Per beneficiary

n/a

$695.29 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$14,601

Part B: Ycanth (Cantharidin) · HCPCS J7354

2024 spending

$30K

Beneficiaries

16

27 claims

Per beneficiary

$1,898

2024 ASP limit $715.67 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$30,374

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 51 on PubMed

Sponsor: Verrica Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.